CME Group
CME
$262.63
-1.33%
CME Group Inc. operates global financial markets, providing trading and clearing services for futures and options across interest rates, equity indexes, foreign exchange, energy, metals, and agricultural commodities. As the world's largest derivatives exchange, CME holds a dominant market position, with exclusive rights to trade and clear S&P futures through its 27% stake in S&P Dow Jones Indices. The current investor narrative centers on the impact of a hawkish Federal Reserve, with rising rate hike expectations in 2026 driving increased trading volumes and volatility, which historically benefits CME's transaction-based revenue. However, concerns about a potential economic slowdown and the sustainability of market activity create debate about the durability of this growth.…
CME
CME Group
$262.63
Related headlines
Investment Opinion: Should I buy CME Today?
Rating: Buy. The thesis is that CME's dominant exchange franchise, accelerating revenue growth (14.5% YoY), and high margins (operating 64.9%) justify a premium valuation, with analyst consensus at Buy and an average target of $283.93 (6% upside). Supporting evidence: forward PE of 20.7x is reasonable for expected EPS growth of ~18% (trailing PE 24.4x), revenue growth is accelerating from $1.54B to $1.88B over four quarters, and free cash flow of $4.33B supports a 4.0% dividend yield. The stock trades at a premium to the market (PS 15.1x vs. S&P 500 ~3x), but its defensive characteristics and pricing power warrant it. Key risks: a dovish Fed pivot reducing volumes, valuation compression if growth decelerates, and high payout ratio limiting flexibility. This Buy would downgrade to Hold if forward PE exceeds 25x or revenue growth falls below 10%, and upgrade to Strong Buy if the Fed signals sustained rate hikes. Overall, CME is fairly valued relative to its growth and quality, with modest upside to analyst targets.
Sign up to view all
CME 12-Month Price Forecast
The AI model leans bullish on CME due to the strong fundamental momentum and the likelihood of continued Fed hawkishness, which directly benefits trading volumes. The valuation is not excessive given the growth, and the low beta makes it a defensive addition. However, the medium confidence reflects the binary nature of Fed policy—if the Fed pivots dovish, the thesis weakens significantly. The stance would upgrade to high confidence if Q2 earnings show revenue growth above 15% and the Fed signals more hikes; it would downgrade to neutral if rate hike probabilities drop below 50%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $283.93 and implied upside of +8.1% versus the current price.
Average Target
$283.93
0 analysts
Implied Upside
+8.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$230 - $330
Analyst target range
The target price range spans from a low of $230.00 to a high of $330.00, indicating a wide dispersion of expectations. The high target of $330.00 assumes that CME will benefit from sustained market volatility and rate hikes, driving revenue and earnings growth, while the low target of $230.00 prices in a potential slowdown in trading volumes or a market downturn. Recent ratings actions have been positive, with upgrades from Keefe, Bruyette & Woods (to Outperform) and Rothschild & Co (to Buy), while others have maintained their ratings. The wide target spread suggests significant uncertainty about the future direction of interest rates and market activity, but the overall sentiment remains constructive.
Bulls vs Bears: CME Investment Factors
CME presents a balanced risk/reward. The bull case is anchored by accelerating revenue growth (14.5% YoY), exceptional margins (operating margin 64.9%), and a defensive low beta (0.28), supported by a Buy consensus and a 4% dividend yield. The bear case centers on valuation (forward PE 20.7x) and the cyclicality of trading volumes tied to Fed policy, with the stock already down 3.8% over the past year. The key tension is whether sustained rate-hike-driven volatility can justify the premium valuation, or if a dovish pivot will compress volumes and earnings. Currently, the bullish evidence is slightly stronger given the momentum in revenue and analyst upgrades, but the risk of a Fed policy shift remains the critical swing factor.
Bullish
- Revenue growth accelerating: Q1 2026 revenue of $1.88B grew 14.5% YoY, the fastest pace in recent quarters, driven by higher trading volumes in interest rate and equity index products amid Fed rate hike expectations.
- High profitability and margins: Operating margin of 64.9% and net margin of 62.0% reflect CME's asset-light exchange model, with gross margin at 86.1% and strong operating leverage.
- Analyst consensus is Buy: With 15 analysts, the consensus rating is 'buy' (mean 2.44), and the average target of $283.93 implies ~6% upside from the current $267.79, with a high target of $330 (23% upside).
- Low beta offers defensive appeal: Beta of 0.28 indicates low market correlation, making CME a defensive play in volatile markets, as seen in its 1-month relative strength of +15.8% vs S&P 500.
Bearish
- Valuation premium to market: Trailing PE of 24.4x and forward PE of 20.7x are above the S&P 500's ~20x trailing, and the PEG of 1.59 suggests the market already prices in strong growth.
- Revenue concentration in rates: Interest rate products are a major revenue driver; a dovish Fed pivot or reduced rate volatility could sharply reduce trading volumes, as seen in the 33% drawdown from the 52-week high.
- High payout ratio limits reinvestment: With a payout ratio of 97.2%, CME returns nearly all earnings to shareholders, leaving little room for organic growth investments or buffer against earnings declines.
- Recent price weakness: The stock is down 3.8% over the past year and 7.4% over the past 3 months, underperforming the S&P 500 (up 18.2% 1Y), indicating negative momentum.
CME Technical Analysis
CME's stock has experienced a volatile year, with a 1-year price change of -3.77%, reflecting a broad decline from its 52-week high of $329.16 to a low of $218.31. The current price of $267.79 sits at approximately 81% of the 52-week range, indicating a recovery from the lows but still well below the peak. This positioning suggests the stock is in a recovery phase, having rebounded from a significant drawdown of -33.05%, yet it remains in a longer-term downtrend as the price is below the midpoint of its range.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
-8.5%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | +3.6% |
| 3m | -8.9% | +5.1% |
| 6m | -11.7% | +13.8% |
| 1y | -8.5% | +22.2% |
| ytd | -2.6% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue has shown robust growth, with the most recent quarter (Q1 2026) reporting revenue of $1.88 billion, a 14.48% year-over-year increase. This growth is accelerating, as prior quarters saw revenue of $1.65 billion (Q4 2025), $1.54 billion (Q3 2025), and $1.69 billion (Q2 2025), indicating a strong upward trajectory. The growth is driven by increased trading volumes in interest rate and equity index products, reflecting heightened market volatility and rate hike expectations. This revenue momentum is a positive signal for the investment case, suggesting that CME is benefiting from the current macroeconomic environment.
Quarterly Revenue
$1.9B
2026-03
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
88.1%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 24.43x, while the forward PE is 20.70x, indicating that the market expects earnings growth of approximately 18% over the next year. This gap between trailing and forward multiples suggests that investors are pricing in continued earnings expansion, driven by strong revenue growth and operating leverage. The forward PE of 20.70x is below the trailing multiple, which is a positive signal for value investors, as it implies that the stock is becoming more attractive on an earnings basis.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderate. CME's debt-to-equity is low at 0.13, and its current ratio of 93.0 indicates ample liquidity. However, the payout ratio of 97.2% leaves minimal retained earnings for reinvestment, and any earnings decline could force dividend cuts. Revenue is highly dependent on trading volumes, which are sensitive to interest rate expectations; a 14.5% revenue growth in Q1 2026 could reverse if volatility subsides. The high net margin of 62% also means operating leverage works both ways—a 10% revenue drop could disproportionately hit earnings.
FAQ
The key risks are: (1) Financial: high payout ratio of 97.2% limits reinvestment and could force dividend cuts if earnings decline. (2) Market/Competitive: a dovish Fed pivot could reduce trading volumes, as seen in the 33% drawdown from the 52-week high. (3) Macro: rising recession risk from rate hikes could dampen overall market activity. (4) Company-specific: revenue concentration in interest rate products makes CME sensitive to rate volatility. The most severe risk is a prolonged period of low volatility, which could compress earnings and the stock's premium valuation.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading around $283.93 (analyst average target), implying ~6% upside. The bull case (30% probability) targets $300-$330 if the Fed continues hiking and volumes surge. The bear case (20% probability) sees the stock falling to $220-$250 if the Fed pivots dovish and volumes decline. The most likely scenario is the base case, assuming the Fed maintains a hawkish stance with pauses. Overall, the expected return is positive, but investors should monitor Fed policy signals closely.
CME is fairly valued relative to its growth and quality. The trailing PE of 24.4x and forward PE of 20.7x are above the S&P 500's ~20x trailing, but the PEG ratio of 1.59 suggests the premium is justified by expected growth. The PS ratio of 15.1x is high compared to the market, reflecting its high margins (net margin 62%). Historically, CME has traded at a premium due to its defensive characteristics and pricing power. The market is pricing in continued earnings growth of ~18%, which is achievable if revenue growth stays above 10%. Thus, the stock is not overvalued, but it is not a bargain either.
Yes, CME is a good buy for investors seeking a defensive growth stock with income. The analyst consensus is Buy, with an average target of $283.93 (6% upside) and a high target of $330 (23% upside). The stock trades at a forward PE of 20.7x, which is reasonable for expected EPS growth of ~18%, and offers a 4.0% dividend yield. The main risk is a dovish Fed pivot that could reduce trading volumes, but the low beta (0.28) and strong free cash flow ($4.33B) provide downside support. It is particularly suitable for long-term investors who can tolerate short-term volatility in exchange volumes.
CME is suitable for long-term investment due to its defensive characteristics, low beta (0.28), and consistent dividend yield (4.0%). The stock has a history of recovering from drawdowns, and its exchange franchise provides durable competitive advantages. Short-term trading is possible given the volatility around Fed decisions, but the low beta means it may underperform in strong bull markets. A minimum holding period of 3-5 years is recommended to ride out interest rate cycles and benefit from the compounding of dividends and earnings growth. For income-focused investors, CME is a core holding.